A federal panel of experts has recommended expanding vaccinations for respiratory syncytial virus (RSV) in adults and introducing a new combination vaccine as an option for protecting teenagers against meningitis. The Advisory Committee on Immunization Practices also advised a vaccine to safeguard travelers against the mosquito-borne illness chikungunya. However, the decision on whether to adopt these recommendations remains uncertain.
The 15-member panel advises the Centers for Disease Control and Prevention (CDC) director on the application of regulator-approved vaccines. Typically, CDC directors approve these recommendations. Susan Monarez, appointed by the Trump administration as the acting CDC director in January, is awaiting Senate confirmation to officially lead the agency. Due to federal regulations concerning vacancies, Monarez has recused herself from regular duties, prompting any recommendations made by the committee to potentially be decided by U.S. Health Secretary Robert F. Kennedy Jr., a notable figure in the U.S. anti-vaccine discourse. A spokesperson for the Department of Health and Human Services has indicated that the agency is evaluating how to proceed with the panel’s recommendations.
The recommendations from the panel include the following:
- Allowing individuals aged 50 to 59 with conditions such as heart disease, diabetes, and chronic obstructive pulmonary disorder to receive RSV vaccinations.
- Endorsing a new combination vaccine developed by GSK, which protects against five strains of meningococcal bacteria, including one that led to several outbreaks on college campuses approximately a decade ago. This vaccine would complement existing products targeting these bacteria.
- Adding a second chikungunya vaccine option for Americans aged 12 and older traveling to countries experiencing outbreaks. Annually, around 100 to 200 U.S. travelers report cases of chikungunya.
- Issuing a new precaution for the older chikungunya vaccine, which utilizes a weakened but live virus, advising individuals aged 65 and older to carefully consider the risks and benefits of this version. This precaution follows an investigation into six reports of adverse heart or brain symptoms in older individuals with pre-existing medical conditions within a week of vaccination.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP maintains sole responsibility for its content.
The Broader Implications
The panel’s recommendations have the potential to significantly impact public health, particularly for at-risk populations. Expanding RSV vaccinations to older adults with existing health conditions could reduce the incidence of severe respiratory illness, thereby alleviating some pressure on healthcare systems. Additionally, the introduction of a new meningococcal vaccine provides enhanced protection against bacterial strains that have historically affected young people in communal living situations, such as college dormitories.
For travelers, the availability of an additional chikungunya vaccine enhances protection against a disease prevalent in certain regions, potentially reducing the number of cases brought into the United States. These measures reflect a proactive approach to public health, aiming to curtail the spread of infectious diseases and safeguard vulnerable groups. As these recommendations await approval, their implementation could influence vaccine policy and practice, shaping the future landscape of public health initiatives.
